Japan-listed stock of Shin Nippon (SNBL), which acquired the drug through its purchase of Satsuma Pharmaceuticals in April last year, was down 12.2% at 1,721 yen ($11.64) at Thursday's close. SNBL said the complete response letter from the Food and Drug Administration (FDA) did not indicate any concerns related to the data nor was there any request for additional information.
With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
You to nights I noticed the newest Tohoku Rakuten Eagles win a house video game from the Rakuten Seimei Playground Miyagi | Setúbal na Rede setubalnarede.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from setubalnarede.pt Daily Mail and Mail on Sunday newspapers.
Form 8-K Satsuma Pharmaceuticals, For: Jun 06 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.